FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascular Death in Adults with Type 2 Diabetes

December 2, 2016 -- The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news